Mycobacterial interferon-γ release variations during longterm treatment with tumor necrosis factor blockers: Lack of correlation with clinical outcome

Journal of Rheumatology

Volumn 40, Issue 2, 2013, Pages 157-165

  Scrivo, Rossana ^a,d   Sauzullo, Ilaria ^b   Mengoni, Fabio ^b   Priori, Roberta ^a   Coppola, Mariateresa ^a   Iaiani, Giancarlo ^b   Franco, Manuela Di ^a   Vullo, Vincenzo ^b   Mastroianni, Claudio Maria ^c   Valesini, Guido ^d  

^a Dipartimento di Medicina Interna   (Italy)

^b Dipartimento di Sanità Pubblica Veterinaria e Sicurezza Alimentare   (Italy)

^c UOC Malattie Infettive   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Quantiferon tb gold in tube tests; Rheumatic diseases; Tuberculin skin test; Tuberculosis; Tumor necrosis factor blockers

Indexed keywords

ABATACEPT; ADALIMUMAB; BCG VACCINE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; ISONIAZID; RITUXIMAB; TUMOR NECROSIS FACTOR INHIBITOR;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BEHCET DISEASE; FEMALE; HUMAN; INTERFERON GAMMA RELEASE ASSAY; LATENT TUBERCULOSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY; TUBERCULIN TEST;

ADULT; AGED; AGED, 80 AND OVER; ANTIRHEUMATIC AGENTS; FEMALE; HUMANS; INTERFERON-GAMMA RELEASE TESTS; LATENT TUBERCULOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REPRODUCIBILITY OF RESULTS; RHEUMATIC DISEASES; TREATMENT OUTCOME; TUBERCULIN TEST; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84873591198     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.120688     Document Type: Article

References (57)

1. Mazurek GH, Jereb J, Vernon A, Lo Bue P, Goldberg S, Castro K; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep 2010;59 RR-5:1-25.
2. Herrera V, Perry S, Parsonnet J, Banaei N. Clinical application and limitations of interferon-gamma release assays for the diagnosis of latent tuberculosis infection. Clin Infect Dis 2011;52:1031-7.
3. Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Inf Dis 2003;3:148-55.
4. Gómez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD; BIOBADASER Group. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2003;48:2122-7.
5. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
6. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Bréban M, et al. Research Axed on Tolerance of Biotherapies Group. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60: 1884-94.
7. Takahashi H, Shigehara K, Yamamoto M, Suzuki C, Naishiro Y, Tamura Y, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. Rheumatol Int 2007;27:1143-8.
8. Chen DY, Shen GH, Hsieh TY, Hsieh CW, Lan JL. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. Arthritis Rheum 2008;59:800-6.
9. Matulis G, Juni P, Villiger PM, Gadola SD. Detection of latent tuberculosis in immunosuppressed patients with autoimmune diseases: Performance of a Mycobacterium tuberculosis antigen-specific interferon gamma assay. Ann Rheum Dis 2008;67:84-90.
10. Ponce de Leon D, Acevedo-Vasquez E, Alvizuri S, Gutierrez C, Cucho M, Alfaro J, et al. Comparison of an interferon-gamma assay with tuberculin skin testing for detection of tuberculosis (TB) infection in patients with rheumatoid arthritis in a TB-endemic population. J Rheumatol 2008;35:776-81.
11. Vassilopoulos D, Stamoulis N, Hadziyannis E, Archimandritis AJ. Usefulness of enzyme-linked immunospot assay (Elispot) compared to tuberculin skin testing for latent tuberculosis screening in rheumatic patients scheduled for anti-tumor necrosis factor treatment. J Rheumatol 2008;35:1271-6.
12. Inanc N, Aydin SZ, Karakurt S, Atagunduz P, Yavuz S, Direskeneli H. Agreement between Quantiferon-TB gold test and tuberculin skin test in the identification of latent tuberculosis infection in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol 2009;36:2675-81.
13. Laffitte E, Janssens JP, Roux-Lombard P, Thielen AM, Barde C, Marazza G, et al. Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: Comparison of an interferon-gamma release assay vs. tuberculin skin test. Br J Dermatol 2009;161:797-800.
14. Murakami S, Takeno M, Kirino Y, Kobayashi M, Watanabe R, Kudo M, et al. Screening of tuberculosis by interferon-gamma assay before biologic therapy for rheumatoid arthritis. Tuberculosis 2009;89:136-41.
15. Park JH, Seo GY, Lee JS, Kim TH, Yoo DH. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. J Rheumatol 2009;36:2158-63.
16. Soborg B, Ruhwald M, Hetland ML, Jacobsen S, Andersen AB, Milman N, et al. Comparison of screening procedures for Mycobacterium tuberculosis infection among patients with inflammatory diseases. J Rheumatol 2009;36:1876-84.
17. Martin J, Walsh C, Gibbs A, McDonnell T, Fearon U, Keane J, et al. Comparison of interferon (gamma) release assays and conventional screening tests before tumour necrosis factor (alpha) blockade in patients with inflammatory arthritis. Ann Rheum Dis 2010;69:181-5.
18. Casas S, Andreu A, Juanola X, Bordas X, Alcaide F, Moure R, et al. Diagnosis of tuberculosis infection by tuberculin skin test and a whole-blood interferon-release assay in patients considered for anti-tumor necrosis factor-therapy. Diagn Microbiol Infect Dis 2011;71:57-65.
19. Kleinert S, Kurzai O, Elias J, Marten K, Engelke C, Feuchtenberger M, et al. Comparison of two interferon-gamma release assays and tuberculin skin test for detecting latent tuberculosis in patients with immune-mediated inflammatory diseases. Ann Rheum Dis 2010;69:782-4.
20. Lalvani A, Millington KA. Screening for tuberculosis infection prior to initiation of anti-TNF therapy. Autoimmun Rev 2008;8:147-52.
21. Bartalesi F, Vicidomini S, Goletti D, Fiorelli C, Fiori G, Melchiorre D, et al. Quanti FERON-TB Gold and the TST are both useful for latent tuberculosis infection screening in autoimmune diseases. Eur Respir J 2009;33:586-93.
22. Kwakernaak AJ, Houtman PM, Weel JF, Spoorenberg JP, Jansen TL. A comparison of an interferon-gamma release assay and tuberculin skin test screened for latent tuberculosis prior to the initiation of a first tumor necrosis factor inhibitor. Clin Rheumatol 2011;30:505-10.
23. Lange B, Vavra M, Kern WV, Wagner D. Development of tuberculosis in immunocompromised patients with a positive tuberculosis-specific IGRA. Int J Tuberc Lung Dis 2012;16:492-5.
24. Mínguez S, Latorre I, Mateo L, Lacoma A, Diaz J, Olivé A, et al. Interferon-gamma release assays in the detection of latent tuberculosis infection in patients with inflammatory arthritis scheduled for anti-tumour necrosis factor treatment. Clin Rheumatol 2012;31:785-94.
25. Kleinert S, Tony HP, Krueger K, Detert J, Mielke F, Rockwitz K, et al. Screening for latent tuberculosis infection: Performance of tuberculin skin test and interferon-release assays under real-life conditions. Ann Rheum Dis 2012;71:1791-5.
26. Menzies D. Interpretation of repeated tuberculin tests. Boosting, conversion, and reversion. Am J tuberculin skin testing on a Mycobacterium tuberculosis-specific interferon-gamma assay. Eur Respir J 2007;29:1212-6.
27. Richeldi L, Bergamini BM, Vaienti F. Prior tuberculin skin testing does not boost Quanti FERON-TB results in paediatric contacts. Eur Respir J 2008;32:524-5.
28. Sauzullo I, Massetti AP, Mengoni F, Rossi R, Lichtner M, Ajassa C, et al. Influence of previous tuberculin skin test on serial IFN-release assays. Tuberculosis 2011;91:322-6.
29. Kim KH, Lee SW, Chung WT, Kim BG, Woo KS, Han JY, et al. Serial interferon-gamma release assays for the diagnosis of latent tuberculosis infection in patients treated with immunosuppressive agents. Korean J Lab Med 2011;31:271-8.
30. Garcovich S, Ruggeri A, D'Agostino M, Ardito F, De Simone C, Delogu G, et al. Clinical applicability of Quantiferon-TB-Gold testing in psoriasis patients during long-term anti-TNF-alpha treatment: A prospective, observational study. J Eur Acad Dermatol Venereol 2011 Sep 16 (E-pub ahead of print).
31. Ringrose JS, Sanche SE, Taylor-Gjevre RM. Detecting latent tuberculosis infection during anti-tumor necrosis factor therapy. Clin Exp Rheumatol 2011;29:790-4.
32. Chen DY, Shen GH, Chen YM, Chen HH, Hsieh CW, Lan JL. Biphasic emergence of active tuberculosis in rheumatoid arthritis patients receiving TNF (alpha) inhibitors: The utility of IFN (gamma) assay. Ann Rheum Dis 2012;71:231-7.
33. Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America (IDSA), September 1999, and the sections of this statement. Am J Respir Crit Care Med 2000;161:S221-47.
34. Carmona L, Gómez-Reino JJ, Rodríguez-Valverde V, Montero D, Pascual-Gómez E, Mola EM, et al, on behalf of the BIOBADASER Group. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum 2005;52:1766-72.
35. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al, for the START Study Group. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: A large, randomized, placebo-controlled trial. Arthritis Rheum 2006;54:1075-86.
36. Hsia EC, Cush JJ, Matteson EL, Beutler A, Doyle MK, Hsu B, et al. A comprehensive tuberculosis screening program in patients with inflammatory arthritides treated with golimumab, a human anti-TNF antibody, in phase 3 clinical trials. Arthritis Care Res 2012 Jul 10 (E-pub ahead of print).
37. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
38. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H; CASPAR Study Group. Classification criteria for psoriatic arthritis. Development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-73.
39. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
40. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990;335:1078-80.
41. Bélard E, Semb S, Ruhwald M, Werlinrud AM, Soborg B, Jensen FK, et al. Prednisolone treatment affects the performance of the Quanti FERON gold in-tube test and the tuberculin skin test in patients with autoimmune disorders screened for latent tuberculosis infection. Inflamm Bowel Dis 2011;17:2340-9.
42. Hsia EC, Schluger N, Cush JJ, Chaisson RE, Matteson EL, Xu S, et al. Interferon-release assay versus tuberculin skin test prior to treatment with golimumab, a human anti-tumor necrosis factor antibody, in patients with rheumatoid arthritis, psoriatic arthritis, or ankylosing spondylitis. Arthritis Rheum 2012;64:2068-77.
43. Pai M, Kalantri S, Dheda K. New tools and emerging technologies for the diagnosis of tuberculosis. Part I. Latent tuberculosis. Expert Rev Mol Diagn 2006;6:413-22.
44. Denkinger CM, Dheda K, Pai M. Guidelines on interferon-release assays for tuberculosis infection: Concordance, discordance or confusion? Clin Microbiol Infect 2011;17:806-14.
45. Zwerling A, van den Hof S, Scholten J, Cobelens F, Menzies D, Pai M. Interferon-gamma release assays for tuberculosis screening of healthcare workers: A systematic review. Thorax 2012;67:62-70.
46. Wallis RS. Tumour necrosis factor antagonists: Structure, function, and tuberculosis risks. Lancet Infect Dis 2008;8:601-11.
47. Theis VS, Rhodes JM. Review article: Minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2008;27:19-30.
48. Scrivo R, Sauzullo I, Mengoni F, Iaiani G, Vestri AR, Priori R, et al. Serial interferon-release assays for screening and monitoring of tuberculosis infection during treatment with biologic agents. Clin Rheumatol 2012;31:1567-75.
49. Ewer K, Millington KA, Deeks JJ, Alvarez L, Bryant G, Lalvani A. Dynamic antigen-specific T-cell responses after point-source exposure to Mycobacterium tuberculosis. Am J Respir Crit Care Med 2006;174:831-9.
50. Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, Lugos MD, et al. Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection. PLoS Med 2007;4:e192.
51. Pai M, Joshi R, Dogra S, Zwerling AA, Gajalakshmi D, Goswami K, et al. T-cell assay conversions and reversions among household contacts of tuberculosis patients in rural India. Int J Tuberc Lung Dis 2009;13:84-92.
52. Ringshausen FC, Nienhaus A, Schablon A, Schlösser S, Schultze-Werninghaus G, Rohde G. Predictors of persistently positive Mycobacterium-tuberculosis-specific interferon-gamma responses in the serial testing of health care workers. BMC Infect Dis 2010;10:220.
53. Casas I, Latorre I, Esteve M, Ruiz-Manzano J, Rodriguez D, Prat C, et al. Evaluation of interferon-gamma release assays in the diagnosis of recent tuberculosis infection in health care workers. PLoS ONE 2009;4:e6686.
54. Carrara S, Vincenti D, Petrosillo N, Amicosante M, Girardi E, Goletti D. Use of a T cell-based assay for monitoring efficacy of antituberculosis therapy. Clin Infect Dis 2004;38:754-6.
55. Katiyar SK, Sampath A, Bihari S, Mamtani M, Kulkarni H. Use of the Quanti FERON-TB Gold In-Tube test to monitor treatment efficacy in active pulmonary tuberculosis. Int J Tuberc Lung Dis 2008;12:1146-52.
56. Sauzullo I, Mengoni F, Lichtner M, Massetti AP, Rossi R, Iannetta M, et al. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response. PLoS One 2009;4:e5187.
57. Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, et al; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther 2006;8:R114.